Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals third-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded on Monday, November 18, ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...

JPMorgan says Astellas Pharma’s (ALPMY) (ALMPY) announcement that the FDA has issued a Complete Response Letter regarding for Izervay in ...

Q3 2024 Earnings Call Transcript November 18, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the NRx ...

The settlement resolves all patent litigation brought by BeiGene against companies that sought to market generic versions of BRUKINSA. BeiGene and Sandoz Inc. previously filed a joint stipulation to ...

The thermochromic labels market is poised for significant growth over the next decade, with a projected compound annual ...

Weight-loss drugs promise to make the pounds melt away, and beauty products and fillers will erase those fine lines. But do you know what you're getting or where it's coming from?

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also ...